New Urine Test Detects High-Grade Prostate Cancer
The new urine-based test aims to differentiate between slow-growing and aggressive forms of prostate cancer.
The new urine-based test aims to differentiate between slow-growing and aggressive forms of prostate cancer.
ArteraAI says the CMS decided on the payment rate for the ArteraAI Prostate Test, a clinical diagnostic laboratory test for prostate cancer.
To explore why prostate cancer disproportionately harms Black men, researchers looked to another disorder, diabetes, which alters metabolism.
The accuracy of PSA in prostate cancer screening can be improved by accounting for genetic factors that are not associated with cancer.
Read MoreExperts argue that “test by request” have led to higher PSA testing and clear medical harm, with minimal benefit and inequity.
Read MoreLevels of PSA are low in healthy men but elevate in the presence of prostate cancer and other mentioned conditions.Â
Read MoreA new minimally invasive prostate biopsy procedure reduces the risk of infection, improves imaging for accuracy, and may increase cancer detection in a clinic setting.
Read MoreThe American Urological Association and Society of Urologic Oncology have released the 2023 clinical practice guideline on the early detection of prostate cancer.
Read MoreA new study informed use of PARP inhibitors beyond BRCA1/2-deficient tumors and reevaluated biomarkers for PARP inhibition in prostate cancer.
Read MoreA rapid test for advanced prostate cancer can quickly identify people with “actionable” gene variants eligible for new targeted therapies.
Read MoreWith data showing an increase in advanced prostate cancer cases, doctors at ProCure are urging men over age 55 to get their annual screening.
Read MoreVeracyte CEO Marc Stapley outlines how single-cancer testing is giving pathologists, clinicians, and patients an edge.
Read MoreThis model combines profiles of fusion genes in prostate cancer with the Gleason score and prostate-specific antigen (PSA) level.
Read MoreCleveland Diagnostics announced an agreement with Quest Diagnostics to expand patient access to its novel prostate cancer test, IsoPSA.
Read MoreLynxDx is introducing a non-invasive, data-driven, urine prostate cancer screening test to guide clinical decisions for patients.
Read MoreResearchers at the University of East Anglia helped develop a blood test to detect prostate cancer with greater accuracy than current methods.
Read MoreInvestigators found that the test was able to distinguish cancer localized to the prostate from cancer that spread to other parts of the body.
Read MoreShifting guidelines for prostate cancer screening lead to uncertainty on when and if prostate screening tests should be ordered.
Read More